| ￥2600 | |
| Z06026-100 | |
|
|
|
|
|
|
|
|
|
| Species | Mouse | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its ability to cleave a fluorogenic peptide substrate, McaSEVNLDAEFRK(Dpn)RRNH2. Test result meets the standard. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 49.49 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 60-70 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
The purity of BACE-1, His, Mouse is greater than 95% as determined by SEC-HPLC. »
BACE-1, His, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | The beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1) initiates the generation of amyloid-β (Aβ), and the amyloid cascade leading to amyloid plaque deposition, neurodegeneration, and dementia in Alzheimer's disease (AD). Clinical failures of anti-Aβ therapies in dementia stages suggest that treatment has to start in the early, asymptomatic disease states. |
| Synonyms | Beta-secretase 1; ASP2; Asp 2; BACE1; BACE; FLJ90568; HSPC104; KIAA1149; Memapsin-2; BACE-1; EC 3.4.23; EC 3.4.23.46;β-secretase 1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
